News
AMPH
21.04
+0.10%
0.02
New Strong Sell Stocks for June 23rd
NASDAQ · 3d ago
Weekly Report: what happened at AMPH last week (0615-0619)?
Weekly Report · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-RBB Bancorp, Roblox, Open Lending
Reuters · 06/16 17:52
Amphastar Pharmaceuticals Gets FDA Approval for Over-The-Counter Nasal Spray for Opioid Overdose
Dow Jones · 06/16 16:50
BUZZ-U.S. STOCKS ON THE MOVE-Amkor Technology, Dynatrace, Corvex
Reuters · 06/16 15:38
BUZZ-Amphastar rises after FDA approves new over-the-counter overdose spray
Reuters · 06/16 13:15
FDA: APPROVED OTC INTRANASAL NALOXONE PRODUCT, REXTOVY, A 4 MG NALOXONE HYDROCHLORIDE NASAL SPRAY FOR EMERGENCY TREATMENT OF OPIOID OVERDOSE
Reuters · 06/16 12:46
Weekly Report: what happened at AMPH last week (0608-0612)?
Weekly Report · 06/15 10:03
1 Healthcare Stock to Consider Right Now and 2 We Brush Off
Barchart · 06/12 03:36
Emergent BioSolutions: Down 40%+ From Recent Highs And Likely More To Come
Seeking Alpha · 06/08 21:27
Weekly Report: what happened at AMPH last week (0601-0605)?
Weekly Report · 06/08 10:00
Amphastar Shareholders Approve Directors, Auditor and Pay Practices
TipRanks · 06/03 21:41
Amphastar Pharmaceuticals holds annual shareholder meeting
PUBT · 06/03 20:18
Amphastar Pharmaceuticals Is Maintained at Equal-Weight by Barclays
Dow Jones · 06/03 13:20
Amphastar Pharmaceuticals Price Target Cut to $20.00/Share From $23.00 by Barclays
Dow Jones · 06/03 13:20
Barclays Maintains Equal-Weight on Amphastar Pharma, Lowers Price Target to $20
Benzinga · 06/03 13:10
Amphastar price target lowered to $20 from $23 at Barclays
TipRanks · 06/03 09:43
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX), Ardent Health Partners, Inc. (ARDT) and Amphastar Pharmaceuticals (AMPH)
TipRanks · 06/03 08:20
Amphastar posts Jefferies healthcare conference deck highlighting pipeline shift toward proprietary drugs and biosimilars
PUBT · 06/02 21:23
Weekly Report: what happened at AMPH last week (0525-0529)?
Weekly Report · 06/01 10:03
More
Webull provides a variety of real-time AMPH stock news. You can receive the latest news about Amphastar Pharma through multiple platforms. This information may help you make smarter investment decisions.
About AMPH
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.